Abiopharma

🔍 Jimenez Freddy A. (Executive)

Company: Celldex Therapeutics, Inc. (CLDX)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 93,000 shares of Incentive Stock Option (right to buy) at $34.09 per share (Derivative)
  Date: 2026-06-25 | Code: A | Expires: 2036-06-25 | Exercise: 2027-06-25 | equity_swap_involved: 0 | shares_owned_after: 93,000.00 | transaction_form_type: 4 | Footnotes: F1, F1, F2

Footnotes:

• F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
• F2: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.